Bone Cancer Clinical Trial
Official title:
Examining Patient Involvement Patterns and Trends in Participation in Bone Cancer Clinical Trials
| NCT number | NCT06070259 |
| Other study ID # | 72278769 |
| Secondary ID | |
| Status | Not yet recruiting |
| Phase | |
| First received | |
| Last updated | |
| Start date | October 2024 |
| Est. completion date | October 2026 |
Clinical studies, with a distinct focus on bone cancer, play a crucial role in evaluating the safety and effectiveness of novel treatments for this disease. These trials serve as instrumental means to determine whether new medications surpass conventional therapies, providing substantial evidence for their broader adoption. The primary objective is to meticulously scrutinize trial completion rates and voluntary withdrawals within this specific patient group.
| Status | Not yet recruiting |
| Enrollment | 500 |
| Est. completion date | October 2026 |
| Est. primary completion date | October 2025 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: - Aged = 18 years old and ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed - Diagnosis of bone cancer - No prior treatment for bone cancer Exclusion Criteria: - Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial - Enrolled in another research study - Inability to provide written informed consent |
| Country | Name | City | State |
|---|---|---|---|
| United States | Power Life Sciences | San Francisco | California |
| Lead Sponsor | Collaborator |
|---|---|
| Power Life Sciences Inc. |
United States,
Niiyama Y, Kawamata T, Yamamoto J, Furuse S, Namiki A. SB366791, a TRPV1 antagonist, potentiates analgesic effects of systemic morphine in a murine model of bone cancer pain. Br J Anaesth. 2009 Feb;102(2):251-8. doi: 10.1093/bja/aen347. Epub 2008 Nov 26. — View Citation
Porta-Sales J, Garzon-Rodriguez C, Llorens-Torrome S, Brunelli C, Pigni A, Caraceni A. Evidence on the analgesic role of bisphosphonates and denosumab in the treatment of pain due to bone metastases: A systematic review within the European Association for Palliative Care guidelines project. Palliat Med. 2017 Jan;31(1):5-25. doi: 10.1177/0269216316639793. Epub 2016 Jul 10. — View Citation
Ventura C, Nunez SV, Goncalves A, Abreu C, Costa L. Bone Health in Metastatic Cancer. Semin Oncol Nurs. 2022 Apr;38(2):151278. doi: 10.1016/j.soncn.2022.151278. Epub 2022 Apr 15. — View Citation
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Rate of patients who decide to enroll in a bone cancer clinical research. | 3 months | ||
| Primary | Number of bone cancer study participants who remain in clinical study until completion. | 12 months |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03905174 -
Massive Implants the Next Generation
|
N/A | |
| Completed |
NCT00160719 -
HLA Sensitization Following Major Cortical Allograft Bone Procedures
|
Phase 4 | |
| Completed |
NCT04974008 -
Osteosarcoma Maintenance Therapy With OST31-164
|
Phase 2 | |
| Completed |
NCT01553539 -
Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery
|
Phase 2 | |
| Recruiting |
NCT03160274 -
Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions
|
||
| Active, not recruiting |
NCT02880319 -
Evaluating Stereotactic Body Radiation Therapy for Oligometastatic Disease of the Bone
|
Phase 2 | |
| Completed |
NCT01135849 -
B-Receptor Signaling in Cardiomyopathy
|
N/A | |
| Terminated |
NCT00960063 -
A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006)
|
Phase 1 | |
| Terminated |
NCT02443103 -
Study Evaluating the Biologic Activity of Guanabenz in Bone Metastasis
|
N/A | |
| Recruiting |
NCT04028479 -
The Registry of Oncology Outcomes Associated With Testing and Treatment
|
||
| Terminated |
NCT03525392 -
Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1.
|
Phase 1 | |
| Terminated |
NCT01541358 -
Sodium Fluoride PET/CT for the Evaluation of Skeletal Cancer
|
N/A | |
| Terminated |
NCT01313884 -
Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma
|
Phase 2 | |
| Completed |
NCT01091883 -
Study Comparing the Safety and Effectiveness of Magnetic Resonance Guided Focused Ultrasound (MRgFUS) and External Beam Radiation (EBRT) for Treatment of Metastatic Bone Tumors and Multiple Myeloma
|
N/A | |
| Terminated |
NCT00127387 -
Enbrel Versus Placebo With Radiation Therapy to Combat Fatigue and Cachexia
|
Phase 2/Phase 3 | |
| Not yet recruiting |
NCT03106675 -
MR Imaging- Guided High Intensity Focused Ultrasound (HIFU) Therapy of Bone Metastases
|
N/A | |
| Recruiting |
NCT05830084 -
Phase Ib / Regorafenib With Conventional Chemotherapy/Newly Diagnosed Patients/ Multimetastatic Ewing Sarcoma
|
Phase 1 | |
| Completed |
NCT01085565 -
Focused Ultrasound Surgery in the Treatment of Pain Resulting From Metastatic Bone Tumors With the ExAblate 2100 Conformal Bone System
|
Phase 2 | |
| Recruiting |
NCT04307914 -
Focused Ultrasound and RadioTHERapy for Noninvasive Palliative Pain Treatment in Patients With Bone Metastases
|
N/A | |
| Terminated |
NCT01163539 -
Cyberknife Radiosurgery and Quality of Life
|
N/A |